2020
-
The Current Role of Combination Maintenance Therapy (Pemetrexed and Bevacizumab) in the Era of Immunotherapy
Immune checkpoint inhibitors (ICIs) and molecular targeting drugs used against oncogenic drivers, such as EGFR or ALK, have dramatically changed the treatment of NSCLC.1-6 However, treatment options after those drugs […]
-
Questions Remain Following Long-Term Results of the Phase II SABR-COMET Trial
In Response To: Palma DA, Olson R, Harrow, S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. […]
-
Experts Discuss Benefits, Challenges with Lung Cancer Screening: A Pro/Con
Using LDCT to Boost Lung Cancer Prevention Strategies: A Pro/Con By Ugo Pastorino, MD Now we know from robust randomized trials that systematic screening with low-dose computed tomography (LDCT) of […]
-
Lung Cancer Health Care Delivery, Community Building, and Research: Are They Truly Inclusive?
Lung cancer was first identified as a distinct disease in 1761.1 Since this discovery, we have come a long way—both in terms of progress towards understanding the heterogeneous biology of […]
-
Implications of the PACIFIC Trial in 2020
Approximately one-third of patients with NSCLC are diagnosed with stage III disease.1 Concurrent platinum-based chemotherapy with thoracic radiation (CRT) has been considered the cornerstone of treatment for patients with inoperable […]
-
Good Communication Strategies While Wearing PPE
Lung cancer care providers have traditionally relied on facial gestures to show empathy. With face coverings now the norm, empathy can actually be shown through improved processes.
-
The Immune System: A New Organ at Risk in Lung Cancer Radiation Therapy?
IN REFERENCE TO: Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of radiation dose to the host immune system on tumor control and survival for stage III […]
-
Dr. Kazuhiko Nakagawa Discusses RELAY Study Data, Implications for Practice
Kazuhiko Nakagawa, MD, PhD, is a professor in the Department of Medical Oncology, Kindai University, Faculty of Medicine, in Japan, and he served as the lead principal investigator on the […]
-
Checkpoint Inhibitors in SCLC: Putting the Most Novel Data in Context
Two separate randomized phase III trials have established atezolizumab (IMpower1331 and durvalumab (CASPIAN2) as first-line treatments for extensive-stage (ES) SCLC in combination with chemotherapy followed by these same checkpoint inhibitors (CPIs) […]
-
Multidisciplinary Tumor Boards: Integrating Best Patient Care and Education in Precision Medicine
One of the pillars of organ-specific tumor centers certified by the German Cancer Society, such as lung, breast, and prostate cancer centers, is a weekly multidisciplinary tumor board (MTD). In […]
View ILCN Archives
Provider Resources